You are using an older browser version. Please use a supported version for the best MSN experience.

AFT's pain relief sales more than triple

NZ Newswire logoNZ Newswire 11/05/2017 Paul McBeth

AFT Pharmaceuticals more than tripled sales of its flagship Maxigesic pain relief tablets in the 2017 financial year and anticipates more growth as it taps new markets.

The Auckland-based drug-maker sold 74 million tablets in the year ended March 31, up from 22 million tablets a year earlier, it said on Friday.

The company will report earnings next week, and in March said it expected to generate annual sales of between $69 million and $71m, up from $65.8m a year earlier.

The increase in Maxigesic sales was primarily driven by strong sales growth in existing markets such as Australia, Italy and United Arab Emirates together with a new launch in the key UK market, chief executive Hartley Atkinson says.

"Sales growth going forward for Maxigesic tablets will be fuelled by these new country launches, growing sales from existing markets, and further line extensions such as Maxigesic IV (intravenous), Oral Liquid and Sachets."

In March, the company raised $9.1mn from cornerstone investors CRG and Atkinson's family trust through a redeemable share issue to pay for the international expansion and said it planned to seek more capital through a share purchase plan from existing shareholders.

Separately, AFT said the US Food and Drug Administration accepted its application to register Maxigesic tablets in the US, meaning the New Zealand firm is two-thirds of the way through the regulatory process.

The shares last traded at $2.25 and have dropped 18 per cent so far this year.

image beaconimage beaconimage beacon